Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Cipla-Pfizer alliance cheers investors
Wed, 2 Dec 02:30 pm

The choppy Indian markets ventured into the negative territory for a short while during the previous two hours of trade.  However on account of buying activity witnessed in realty, auto and banking sectors  it managed to rise marginally above the dotted line. Having said that, telecom, IT and FMCG stocks did not find favour amongst investors.

The BSE Sensex and NSE Nifty are currently trading in the positive, up by 30 and 17 points respectively. The BSE-Midcap and BSE-Smallcap are also trading firm, up by around 1.27% and 1.14% respectively. The rupee is trading at 46.28 to the dollar.

Indian drug major Cipla is in talks with Pfizer, world’s largest drug maker and a number of other leading drug makers to supply generic products for their drugs. As an ongoing business strategy, the company is seeking alliance in developing products, regulatory packages and finally marketing and supplying products from its facilities.

It may be noted that Cipla does not market its formulations directly in the US and European markets. It rather follows a partnership model of supplying products through contracts to about 14 global drug makers around the world. Such partnerships are a win-win for both parties. Indian  pharma has gained a lot of attention  from global drug giants as making active pharmaceutical ingredients can at times cost around 50% less in India as compared to the developed markets. Moreover India’s formulation development capabilities are also noteworthy. Stocks from the healthcare sector are trading on a mixed note.

Aluminium stocks like Hindalco, NALCO are finding favour. According to a leading business daily, state-owned aluminium major, NALCO has signed a memorandum of agreement (MOU) with Nuclear Power Corporation of India (NPCIL) to set up nuclear power plants in the country. The company plans to get into the energy sector as a part of diversification to metals and power sectors. The company now aims to diversify into commercial generation and sale of electric power as an independent power producer (IPP) from cleaner nuclear fuel.

It may be noted that NALCO already operates a coal-fired 1,080 MW power plant for captive use in Orissa. With the commissioning of an additional unit, the capacity of this plant is also expected to go up to 1,200 MW by end of this fiscal.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Cipla-Pfizer alliance cheers investors". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.